

# Yesim Gokmen-Polar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2359737/publications.pdf>

Version: 2024-02-01

106  
papers

1,885  
citations

218677

26  
h-index

276875

41  
g-index

106  
all docs

106  
docs citations

106  
times ranked

3333  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	16.8	270
2	Protein kinase C $\delta$ is required for Ras transformation and colon carcinogenesis in vivo. <i>Journal of Cell Biology</i> , 2004, 164, 797-802.	5.2	129
3	HSF1 as a Cancer Biomarker and Therapeutic Target. <i>Current Cancer Drug Targets</i> , 2019, 19, 515-524.	1.6	79
4	Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 673-682.	2.5	73
5	Extrathoracic metastases of thymic origin: a review of 35 cases. <i>Modern Pathology</i> , 2012, 25, 370-377.	5.5	63
6	DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	57
7	EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. <i>Cancer Research</i> , 2003, 63, 3425-9.	0.9	56
8	Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers. <i>Scientific Reports</i> , 2015, 5, 8765.	3.3	55
9	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 4691.	3.3	53
10	Splicing factor <i>ESRP1</i> controls ER $\alpha$ -positive breast cancer by altering metabolic pathways. <i>EMBO Reports</i> , 2019, 20, .	4.5	48
11	Mapping of a Molecular Determinant for Protein Kinase C $\delta$ Isozyme Function. <i>Journal of Biological Chemistry</i> , 1998, 273, 20261-20266.	3.4	46
12	The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases. <i>Modern Pathology</i> , 2013, 26, 1059-1064.	5.5	45
13	Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues. <i>Scientific Reports</i> , 2019, 9, 5624.	3.3	45
14	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. <i>Prostate</i> , 2006, 66, 1498-1511.	2.3	44
15	Ductal carcinoma in situ of breast: update 2019. <i>Pathology</i> , 2019, 51, 563-569.	0.6	43
16	Protein Kinase C $\delta$ as a Therapeutic Target in Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 15-18.	2.2	41
17	Single-cell heterogeneity in ductal carcinoma in situ of breast. <i>Modern Pathology</i> , 2018, 31, 406-417.	5.5	41
18	Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 375-384.	2.5	37

#	ARTICLE	IF	CITATIONS
19	Molecular Analysis of Thymoma. PLoS ONE, 2012, 7, e42669.	2.5	37
20	β-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells. Cancer Research, 2005, 65, 9406-9414.	0.9	36
21	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. Modern Pathology, 2015, 28, 1415-1427.	5.5	36
22	Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clinical and Experimental Metastasis, 2014, 31, 771-786.	3.3	33
23	A Gene Signature to Determine Metastatic Behavior in Thymomas. PLoS ONE, 2013, 8, e66047.	2.5	31
24	Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. Journal of Neuro-Oncology, 2015, 122, 205-216.	2.9	31
25	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal of Clinical Oncology, 2019, 37, 3484-3492.	1.6	30
26	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Modern Pathology, 2015, 28, 677-685.	5.5	28
27	Role of lncRNAs in health and disease—size and shape matter. Briefings in Functional Genomics, 2015, 14, 115-129.	2.7	28
28	2-Methoxyestradiol Inhibits the Anaphase-Promoting Complex and Protein Translation in Human Breast Cancer Cells. Cancer Research, 2007, 67, 702-708.	0.9	24
29	Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Laboratory Investigation, 2012, 92, 1564-1573.	3.7	24
30	Upregulation of HSF1 in estrogen receptor positive breast cancer. Oncotarget, 2016, 7, 84239-84245.	1.8	24
31	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. Scientific Reports, 2020, 10, 12123.	3.3	22
32	Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs.. Journal of Clinical Oncology, 2016, 34, 452-452.	1.6	20
33	Biomarkers for breast cancer stem cells: the challenges ahead. Biomarkers in Medicine, 2011, 5, 661-671.	1.4	17
34	Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	2.5	16
35	Molecular profiling assays in breast cancer: are we ready for prime time?. Oncology, 2012, 26, 350-7, 361.	0.5	16
36	NUT midline carcinomas in the thymic region. Modern Pathology, 2014, 27, 1649-1656.	5.5	12

#	ARTICLE	IF	CITATIONS
37	Tumor Heterogeneity in Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2015, 22, 294-302.	4.3	12
38	Redefining the Target Again: Chemotherapeutics as Vascular Disrupting Agents?. <i>Cancer Cell</i> , 2008, 14, 195-196.	16.8	11
39	Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. <i>PLoS ONE</i> , 2018, 13, e0204658.	2.5	11
40	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. <i>British Journal of Cancer</i> , 2021, 124, 1150-1159.	6.4	11
41	Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate. <i>Molecular Pharmacology</i> , 1996, 49, 1049-57.	2.3	11
42	Polymorphisms associated with the FVIII and FIX genes in the Turkish population. <i>Haemophilia</i> , 1995, 1, 184-189.	2.1	10
43	Insulin sensitizes beta-agonist and forskolin-stimulated lipolysis to inhibition by 2',5'-dideoxyadenosine. <i>American Journal of Physiology - Cell Physiology</i> , 1996, 270, C562-C569.	4.6	9
44	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 633-645.	2.5	9
45	TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1118-1119.	6.3	8
46	The prognostic value of architectural patterns in a study of 37 type AB thymomas. <i>Modern Pathology</i> , 2014, 27, 863-868.	5.5	7
47	EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 17-26.e8.	2.4	7
48	EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. <i>Breast</i> , 2019, 43, 74-80.	2.2	7
49	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 505-505.	1.6	7
50	A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. <i>Proteomics - Clinical Applications</i> , 2007, 1, 18-31.	1.6	6
51	FOXP3 expression and nodal metastasis of breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 405-409.	4.4	6
52	NUT Midline Carcinoma Masquerading As a Thymic Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e126-e129.	1.6	6
53	Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. <i>Oncotarget</i> , 2021, 12, 1178-1186.	1.8	6
54	Is conservative management of ductal carcinoma in situ risky?. <i>Npj Breast Cancer</i> , 2022, 8, 55.	5.2	6

#	ARTICLE	IF	CITATIONS
55	Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy. <i>Journal of Biomedical Optics</i> , 2015, 20, 096016.	2.6	5
56	Multiplexed Protein Analysis. <i>Science Translational Medicine</i> , 2014, 6, 219fs3.	12.4	4
57	Protein Profiling of Breast Cancer for Treatment Decision-Making. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 73-81.	3.8	4
58	Wortmannin converts insulin but not oxytocin from an antilipolytic to a lipolytic agent in the presence of forskolin. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 62-66.	3.4	3
59	Promise of computational systems biology for cancer clinical trials: the voyage to be realized?. <i>Personalized Medicine</i> , 2010, 7, 129-131.	1.5	2
60	Counterpoint: Cancer Stem Cells: Nonbelievers' Viewpoint. <i>Clinical Chemistry</i> , 2013, 59, 208-210.	3.2	2
61	Thymic Carcinomas and Second Malignancies: A Single-Center Review. <i>Cancers</i> , 2021, 13, 2472.	3.7	2
62	Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 607-607.	1.6	2
63	Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).. <i>Journal of Clinical Oncology</i> , 2017, 35, 529-529.	1.6	2
64	RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 634-634.	1.6	2
65	Abstract P2-06-05: LINC00478: A novel tumor suppressor in breast cancer. , 2016, , .		2
66	RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1079-1079.	1.6	2
67	Breast cancer prognostic markers: where are we now?. <i>Medical Laboratory Observer</i> , 2012, 44, 22, 24-5.	0.1	2
68	Inhibition by veratridine of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices. <i>Neurochemical Research</i> , 1995, 20, 1057-1064.	3.3	1
69	Inhibition by NMDA of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices. <i>Neuropharmacology</i> , 1996, 35, 415-421.	4.1	1
70	Tumor marker assessment: Points to ponder. <i>Cancer Biology and Therapy</i> , 2011, 11, 284-286.	3.4	1
71	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptorâ€“Positive, Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz051.	2.9	1
72	INDUCT: A risk score to predict relapse in estrogen-receptorâ€“positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11063-11063.	1.6	1

#	ARTICLE	IF	CITATIONS
73	A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 7106-7106.	1.6	1
74	RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients.. Journal of Clinical Oncology, 2016, 34, 1078-1078.	1.6	1
75	EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer.. Journal of Clinical Oncology, 2017, 35, 579-579.	1.6	1
76	ColotypeR: A tool to classify colon cancers by consensus molecular subtype and subtype-specific risk of recurrence.. Journal of Clinical Oncology, 2018, 36, 632-632.	1.6	1
77	Abstract P5-04-13: Splicing factor ESRP1 controls ER-positive breast cancer progression by altering metabolic pathway genes. , 2019, , .		1
78	Breast cancer prognostic markers: an overview of a changing menu. Medical Laboratory Observer, 2015, 47, 8, 10, 12-3; quiz 14.	0.1	1
79	2648 Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors. European Journal of Cancer, 2015, 51, S529.	2.8	0
80	Treatment of thymic malignanciesâ€”the way forward. Mediastinum, 2018, 2, 17-17.	1.1	0
81	P1.14-17 Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model. Journal of Thoracic Oncology, 2018, 13, S606.	1.1	0
82	Abstract 3489: In silico analysis of angiogenesis pathway as a prognostic tool in breast cancer. , 2011, , .		0
83	P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.. , 2011, , .		0
84	P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.. , 2011, , .		0
85	P2-13-01: Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations.. , 2011, , .		0
86	Abstract 4206: Identification of transcriptional regulatory motifs that control gene expression in premenopausal women with previous history of breast cancer. , 2012, , .		0
87	In silico identification of an epithelial core signature in human tumors.. Journal of Clinical Oncology, 2012, 30, 10628-10628.	1.6	0
88	A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0
89	A gene signature to determine metastatic behavior in thymic carcinoma.. Journal of Clinical Oncology, 2013, 31, 7605-7605.	1.6	0
90	Abstract P5-09-09: ESRP1 and ESRP2 expression in tamoxifen resistance. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
91	Prognostic ability of CD44 expression in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11062-11062.	1.6	0
92	Abstract 4187: Splicing factors ESRP1/ESRP2 as regulators of endocrine resistance in breast cancer. , 2014, , .		0
93	Abstract P3-05-20: ESRP1 adds splice to endocrine resistance. , 2015, , .		0
94	Abstract PD1-7: Differential expression of innate and adaptive immune responses in TNBC outcome. , 2015, , .		0
95	RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy.. Journal of Clinical Oncology, 2015, 33, 1020-1020.	1.6	0
96	Alternative Splicing in Breast Cancer. , 2016, , 365-377.		0
97	Noncoding RNAs in Breast Cancer. , 2016, , 345-364.		0
98	Abstract P1-06-02: Impact of heterogeneity of DCIS on immune cell infiltrations. , 2017, , .		0
99	Phosphopeptide mapping of DLC1 in ER+ breast cancer reveals AMOTL2, a key hippo pathway component, as an important target.. Journal of Clinical Oncology, 2017, 35, 11592-11592.	1.6	0
100	Abstract 1226: Targeting BTK family in ER+ breast cancer with Ibrutinib for personalized precision medicine: a double-edged sword. , 2017, , .		0
101	Abstract 2695: Quantitative phosphoproteome analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor-positive breast cancer. , 2018, , .		0
102	Abstract P4-08-17: Expression score (Escore) for the prediction of likelihood of recurrence of DCIS. , 2019, , .		0
103	CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 598-598.	1.6	0
104	ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.. Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
105	Abstract P2-10-06: Ethnicity-dependent alternative RNA splicing variations of estrogen receptor in breast cancer. , 2020, , .		0
106	Abstract 2109: A novel role for ESRP1 in regulating proliferation in therapy-resistant ER-positive breast cancer. , 2019, , .		0